Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension
Authors:
- Wei XiaWXWei Xia
- Mark D. HolmesMHMark D. Holmes
- Sandra J. HodgeSHSandra J. Hodge
- Sergei DanilovSDSergei Danilov
- David T. CurielDCDavid T. Curiel
- Nicholas W. MorrellNMNicholas W. Morrell
- Paul N. ReynoldsPRPaul N. Reynolds
- 1 May 2007
- journal article
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 292 (5) , L1182-L1192
Abstract
Idiopathic pulmonary arterial hypertension (PAH) is characterized by proliferation of pulmonary vascular endothelial and smooth muscle cells causing increased vascular resistance and right heart failure. Mutations in the bone morphogenetic protein receptor type 2 (BMPR2) are believed to cause the familial form of the disease. Reduced expression of BMPR2 is also noted in secondary PAH. Recent advances in the therapy of PAH have improved quality of life and survival, but many patients continue to do poorly. The possibility of treating PAH via improving BMPR2 signaling is thus a rational consideration. Such an approach could be synergistic with or additive to current treatments. We developed adenoviral vectors containing the BMPR2 gene. Transfection of cells in vitro resulted in upregulation of SMAD signaling and reduced cell proliferation. Targeted delivery of vector to the pulmonary vascular endothelium of rats substantially reduced the pulmonary hypertensive response to chronic hypoxia, as reflected by reductions in pulmonary artery and right ventricular pressures, right ventricular hypertrophy, and muscularization of distal pulmonary arterioles. These data provide further evidence for a role for BMPR2 in PAH and provide a rationale for the development of therapies aimed at improving BMPR2 signaling.Keywords
This publication has 32 references indexed in Scilit:
- Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertensionAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2006
- Targeting endothelial cells with adenovirus expressing nitric oxide synthase prevents elevation of blood pressure in stroke-prone spontaneously hypertensive ratsMolecular Therapy, 2005
- Dysfunctional Smad Signaling Contributes to Abnormal Smooth Muscle Cell Proliferation in Familial Pulmonary Arterial HypertensionCirculation Research, 2005
- Bone Morphogenetic Protein Receptor-2 and Pulmonary Arterial HypertensionCirculation Research, 2005
- Survival with first-line bosentan in patients with primary pulmonary hypertensionEuropean Respiratory Journal, 2005
- BMPR-IIheterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxiaAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2004
- Improved Vascular Gene Transfer With a Helper-Dependent Adenoviral VectorCirculation, 2004
- Pulmonary Hypertension in Transgenic Mice Expressing a Dominant-Negative BMPRII Gene in Smooth MuscleCirculation Research, 2004
- Inhibition of Matrix Metalloproteinases by Lung TIMP-1 Gene Transfer Limits Monocrotaline-Induced Pulmonary Vascular Remodeling in RatsHuman Gene Therapy, 2003
- The Smad pathwayCytokine & Growth Factor Reviews, 2000